Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — MST Access Diagnostics Forum 2022
26 slides from Rhythm Biosciences's conference presentation, Dec 6, 2022
Slide 1: MST Access Diagnostics Forum Presentation
ASX Announcement 6 December 2022 MST Access Diagnostics Forum Presentation Transformative cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (Rhythm or the Company) would like to inform the market of a presentation to MST Access Diagnostics Forum. Please find attached the prese
Slide 2: About Rhythm Biosciences
About Rhythm Biosciences Rhythm Biosciences is focused on becoming a globally significant, transformative, predictive diagnostics company, specialising in cancer detection technology. The Company is currently developing ColoSTAT ® - a simple, low-cost, blood test for global mass market detection of
Slide 3: MST Access Diagnostics Forum Presentation
MST Access Diagnostics Forum Presentation 6 December 2022 ASX:RHY A transformative and predictive cancer diagnostics technology company
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 5: Introduction
Introduction Rhythm’s initial product, ColoSTAT® is a simple, affordable and highly accurate blood test for the detection of colorectal cancer for global mass-market screening. IP protection secured in all major international jurisdictions. Market-ready with operational revenues expected in FY’23. C
Slide 6: ColoSTAT Highlights
ColoSTAT® Highlights Disruptive and transformative technology More affordable and easier to administer Globally addressable markets Performance better than market standard Manufacturing & Patents secured Operational revenues expected in FY’23 Platform Technology Extension Underway 4
Slide 7: Company Overview
Company Overview Capital Structure Share Price Chart ASX Code RHY $7,000,000 $2.50 $6,000,000 Share Price (at 5 December 2022) $1.11 $2.00 $5,000,000 Shares on Issue 216.7 M $1.50 $4,000,000 Unlisted Options 16.8 M $3,000,000 $1.00 Market Capitalisation $241.1 M $2,000,000 $0.50 $1,000,000 Cash in b
Slide 8: Colorectal Cancer (CRC)
Colorectal Cancer (CRC) COLORECTAL CANCER RISK FACTORS Globally, Colorectal Cancer is currently the 3rd largest cancer by volume with 1.93 million new cases diagnosed annually and 2nd largest cause of cancer related deaths AUSTRALIAN OPPORTUNITY “The National Bowel Cancer Screening Program could pre
Slide 9: Market Opportunity / Addressable Market
Market Opportunity / Addressable Market US$39 billion addressable screening value in priority markets1 Colorectal Cancer Screening Market Population Number of people over 50 years of age eligible for screening Country Screening participation Addressable population United States 63% 94 million2 $12Bn
Slide 10: Poor acceptability of faecal tests
Poor acceptability of faecal tests is a significant limitation to the performance of current CRC screening Patients report inconvenience of sample collection, aversion with the procedure and general fear as significant barriers to CRC screening1-3 An observational study1 in over 1,000 people in the
Slide 11: Current CRC screening involves faecal test followed by colonoscopy
Current CRC screening involves the use of a faecal test followed by colonoscopy Abbreviations: CRC, colorectal cancer; FIT, faecal test The FIT pathway consists of a cumbersome multi-step screening process which has a number of limitations1-2: • Self-administered test involving an inconvenient and u
Slide 12: ColoSTAT - Patient Friendly, Increased Compliance
ColoSTAT® - Patient Friendly, Increased Compliance Early detection is the key to survival and reducing the cost of treatment Simple & Routine Patient Journey With ColoSTAT® ColoSTAT® has the potential to: Government screen / GP referral / patient ✓Improve participation in request screening and achie
Slide 13: Blood-based tests preferred over FIT
Blood-based tests, such as ColoSTAT®, are preferred by patients over FIT as they provide a more acceptable way to participate in testing Blood-based tests are preferred over faecal tests (FIT) by 78–93% of people who are offered CRT testing1-5, with ease and convenience being the main reasons for th
Slide 14: ColoSTAT - What Is It? How Does It Work?
ColoSTAT® - What Is It? How Does It Work? Unlike the FIT, ColoSTAT® is specific for colorectal cancer – not just blood in faeces. How it works ColoSTAT® Technology Sample Result Low cost assay format which is designed to integrate with existing pathology lab infrastructure. ColoSTAT® Test-Kit Algori
Slide 15: ColoSTAT Performance
ColoSTAT® Performance ColoSTAT® is expected to increase participation, leading to earlier detection and avoiding costly treatments ColoSTAT® Sensitivity Performance Comparison • Highly Accurate ColoSTAT® was shown to be 35% more accurate at detecting colorectal cancer than the 85% current market sta
Slide 16: Missed detection of early-stage CRC leads to costly healthcare
Missed detection of early-stage CRC leads to the use of costly healthcare for advanced disease Colorectal cancer is associated with high healthcare costs which increase with advanced disease stage at diagnosis1-4 In Australia, the estimated annual cost of The symptoms of CRC only manifest at treatin
Slide 17: Market Likely To Expand Significantly
Market Likely To Expand Significantly ✓ USA Preventative Services Task Force recommends Colorectal Cancer Screening to commence at age 45. Five years younger than it previously recommended, adding circa 20 million patients to the screening population in the USA alone. ✓ Reduction of screening age un
Slide 18: Australia - Growth of CRC in younger age groups
Australia – Growth of CRC in younger age groups 25 – 29 years old 30 – 34 years old 35 – 39 years old 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 0 0 0 1 1 1 2 2 2 3 3 3 4 4 4 5 5 5 6 6 6 7 7 7 8 8 8 9 9 9 10 10 10 11 11 11 12 12 12 13 13
Slide 19: Unique Opportunity To Add Significant Value
Unique Opportunity To Add Significant Value Seamless alignment across the entire value chain providing broader benefits for the health system Blood test is the Patients preferred testing method. Increased participation in screening. Cheaper testing leads to More lives saved. Reduced Government highe
Slide 20: Competitive Landscape - ColoSTAT's Advantage
Competitive Landscape – ColoSTAT®’s Advantage Blood based Epigenomics Novigenix Volition Rx Epi proColon® Colox® Nu.q™ Rhythm ColoSTAT® ~$300 per ~$150 per ~$430 per test test $ TBC test Clinical Genomics Colvera™ ~$400 per test ColoSTAT®’s comparative low cost & simplicity lends itself to global AP
Slide 21: Competitive Landscape - ColoSTAT's Advantage
Competitive Landscape – ColoSTAT®’s Advantage Chart Title 100% 92% 93% 92% 91% 90% 81% 80% 78% 70% 68% 72% Performance / accuracy 60% of ColoSTAT® versus 50% other more expensive, 40% 30% competitor, blood-based 20% tests 10% 0% Colox Colvera Epi proColon ColoSTAT (Study 7) Sensitivity Specificity 1
Slide 22: Market Entry Strategy
Market Entry Strategy Rhythm’s strategy is underpinned by: ✓ Proven technology ✓ Global manufacturing capability ✓ Establish partner networks ✓ Secure commercialisation pathway/s ✓ Partnerships in various global jurisdictions ✓ USA – Two mainstream pathways: ✓ Lab Developed Test (LDT) via a CLIA Lab
Slide 23: Platform Technology Expansion
Platform Technology Expansion • The expansion program is expected to be significantly shortened, leveraging the Company’s lead biomarker which exhibits pan-cancerous properties; • A platform expansion program identified a number of additional cancer target markets that have formed a new Research and
Slide 24: Global Market Opportunity - Platform Expansion
Global Market Opportunity – Platform Expansion Cancer Incidence Addressable Market Opportunity Number of global new cases and deaths in 2020, both sexes, all ages Screening Eligibility by Market [# people] Potential Screening Population Market Value [US$] Breast 2,261,419 US 75M EU 115M China 335M J
Slide 25: Milestones Delivered and Future Catalysts
Milestones Delivered and Future Catalysts Completion of Core CE Mark TGA Inclusion of Clinical trial Commenced the ColoSTAT® technology (Europe) and Submission RHY into the All (Study 7) Platform prototype test- technically expanded to UK (Australia) Ordinaries Index successfully Technology kit vali
Slide 26: Glenn Gilbert
Glenn Gilbert CEO and Managing Director, Rhythm Biosciences glenn.gilbert@rhythmbio.com +61 3 8256 2880 www.rhythmbio.com 24
Rhythm Biosciences — MST Access Diagnostics Forum 2022 on 6ix